| Literature DB >> 30543647 |
Lisa A McSherry1, Eamonn O'Leary1, Stephan U Dombrowski2, Jill J Francis3, Cara M Martin4, John J O'Leary4, Linda Sharp5.
Abstract
BACKGROUND: Primary care practitioners (PCP) play key roles in cervical cancer prevention. Human papillomavirus (HPV) knowledge is an important influence on PCPs' cervical cancer prevention-related behaviours. We investigated HPV knowledge, and associated factors, among general practitioners (GPs) and practice nurses.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30543647 PMCID: PMC6292662 DOI: 10.1371/journal.pone.0208482
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Personal and practice characteristics, and cervical screening related behaviours, of PCPs who participated in the survey, numbers and percentages (or means and standard deviation).
| All PCPs | GPs | Practice Nurses | |||||
|---|---|---|---|---|---|---|---|
| Sex | Female | 604 | 145 | 459 | |||
| Male | 93 | 93 | 0 | ||||
| Number of hours worked per week: mean (sd) | 29.1 (12.2) | 37.6 (14.1) | 25.0 (8.7) | ||||
| Number of years in general practice | <10 years | 298 | 32 | 266 | |||
| 10–19 years | 244 | 78 | 166 | ||||
| 20–39 years | 135 | 112 | 23 | ||||
| 40+ years | 9 | 8 | 1 | ||||
| Ever worked or trained outside Ireland | Yes | 366 | 118 | 248 | |||
| No | 317 | 113 | 204 | ||||
| Practice location | Dublin city | 141 | 52 | 89 | |||
| A city other than Dublin | 76 | 24 | 52 | ||||
| A town | 316 | 102 | 214 | ||||
| A village | 124 | 44 | 80 | ||||
| Other country | 25 | 7 | 18 | ||||
| Solo GP practice | Yes | 118 | 42 | 76 | |||
| No | 566 | 186 | 380 | ||||
| Number of GPs in practice: mean (sd) | 3.3 (2.1) | 3.2 (2.2) | 3.3 (2.1) | ||||
| Any female GP(s)in practice | Yes | 559 | 200 | 359 | |||
| No | 125 | 28 | 97 | ||||
| Any practice nurse(s) in practice | Yes | 181 | 181 | - | |||
| No | 47 | 47 | - | ||||
| Practice has public patient list | Yes | 662 | 214 | 448 | |||
| No | 28 | 17 | 11 | ||||
| Practice specialises in women’s health | Yes | 448 | 155 | 293 | |||
| No | 235 | 77 | 158 | ||||
| Registered smeartaker | Yes | 651 | 212 | 439 | |||
| No | 40 | 20 | 20 | ||||
| Number of cytology tests taken now compared to three years ago | I take about the same | 87 | 47 | 40 | |||
| I take fewer | 91 | 81 | 10 | ||||
| I take more | 471 | 89 | 382 | ||||
| I have never taken a smear | 27 | 11 | 16 | ||||
| Attended smeartaking seminar in past year | Yes | 327 | 61 | 266 | |||
| No | 356 | 167 | 189 | ||||
| Attended HPV seminar in past year | Yes | 106 | 30 | 76 | |||
| No | 540 | 192 | 348 | ||||
1 subjects with missing values for each variable not shown so numbers may not sum to 697; % are of those who responded to the question
2 questions relevant to GPs only
3 i.e. patients with medical cards, which provide free primary care services and subsidized prescription medicines
4 registered with CervicalCheck, the national cervical cancer screening programme
Fig 1Distribution of HPV infection and vaccination knowledge scores among GPs and practice nurses.
(A) HPV infection knowledge. (B) HPV vaccination knowledge.
Significant predictors of low HPV knowledge, numbers and percentages with low scores, multivariable odds ratios (OR) with 95% confidence intervals (CI), and p values for point estimates and from likelihood ratio tests (LRT).
| Low score | OR | 95%CI | p | LRT p | ||||
|---|---|---|---|---|---|---|---|---|
| No. | % | |||||||
| Practitioner type and gender | ||||||||
| Female GP | 5 | 4.2 | 1 | - | - | - | ||
| Male GP | 13 | 16.3 | 5.95 | 1.69 | 20.98 | 0.006 | ||
| Practice Nurse | 93 | 21.8 | 5.75 | 2.13 | 15.49 | 0.001 | <0.001 | |
| Hours worked per week | - | - | 0.95 | 0.94 | 0.98 | 0.000 | <0.001 | |
| Practice has public patient list | ||||||||
| No | 68 | 21.1 | 1.00 | - | - | - | ||
| Yes | 43 | 14.2 | 0.46 | 0.29 | 0.73 | 0.001 | 0.001 | |
| Number of cervical cytology test taken now compared to three years ago | ||||||||
| I take about the same | 4 | 5.1 | 1.00 | - | - | - | ||
| I take fewer | 12 | 15.0 | 5.72 | 1.48 | 22.15 | 0.012 | ||
| I take more | 83 | 18.8 | 3.71 | 1.27 | 10.87 | 0.017 | ||
| I have never taken a smear | 12 | 48.0 | 10.56 | 2.71 | 41.12 | 0.001 | 0.002 | |
| Practitioner type & gender | ||||||||
| Female GP | 8 | 6.7 | 1 | - | - | - | ||
| Male GP | 26 | 32.9 | 3.92 | 1.34 | 11.43 | 0.013 | ||
| Practice Nurse | 84 | 20.4 | 4.63 | 1.86 | 11.52 | 0.001 | <0.001 | |
| Hours worked per week | - | - | 0.98 | 0.95 | 1.00 | 0.032 | 0.030 | |
| Years worked in general practice | - | - | 1.05 | 1.02 | 1.08 | 0.003 | 0.002 | |
| Number of GPs in practice | - | - | 0.87 | 0.77 | 0.99 | 0.030 | 0.023 | |
| Practice specializes in women’s health | ||||||||
| No | 58 | 28.2 | 1 | - | - | - | ||
| Yes | 60 | 14.9 | 0.60 | 0.39 | 0.94 | 0.027 | 0.028 | |
| Number of cervical cytology test taken now compared to three years ago | ||||||||
| I take about the same | 6 | 8.0 | 1 | - | - | - | ||
| I take fewer | 23 | 28.8 | 4.39 | 1.43 | 13.47 | 0.010 | ||
| I take more | 76 | 17.7 | 2.11 | 0.84 | 5.27 | 0.110 | ||
| I have never taken a smear | 13 | 52.0 | 8.51 | 2.53 | 28.69 | 0.001 | 0.002 | |
1 defined as answering ≤5 HPV infection, or ≤4 HPV vaccination, questions correctly
2 p value for point estimate (i.e. test of difference of OR from 1)
3 p value from likelihood ratio test of contribution of variable to multivariate model.
4 OR per unit increase
Responses to individual HPV infection and vaccination knowledge questions for all practitioners, and by practitioner group, with p values from chi-square tests for association between group and whether response was correct.
| Statement | All PCPs | Practitioner Group | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Correct | Incorrect | Correct | Incorrect | Correct | Incorrect | Correct | Incorrect | ||
| a. Genital HPV infection is fairly common in sexually active adults (True) | 82.8% | 17.2% | 91.6% | 8.4% | 80.4% | 19.6% | 80.4% | 19.6% | p = 0.007 |
| b. A person with genital HPV infection may never show symptoms of infection (True) | 91.6% | 8.4% | 99.3% | 0.7% | 94.6% | 5.4% | 88.6% | 11.4% | p<0.001 |
| c. Most genital HPV infections may be cleared without medical intervention (True) | 67.1% | 32.9% | 76.2% | 23.8% | 54.3% | 45.7% | 66.8% | 33.2% | p = 0.002 |
| d. Persistent genital HPV infections in women increase the risk of cervical dysplasia and cervical cancer (True) | 93.9% | 6.1% | 95.8% | 4.2% | 93.5% | 6.5% | 93.4% | 6.6% | p = 0.569 |
| e. Genital HPV infection in men increases risk of penile and other anogenital cancers (True) | 52.8% | 47.2% | 67.8% | 32.2% | 72.8% | 27.2% | 44.0% | 56.0% | p<0.001 |
| f. Treatment of cervical dysplasia/cancer always permanently eliminates the causative infection (False) | 76.7% | 23.3% | 86.0% | 14.0% | 82.6% | 17.4% | 72.5% | 27.5% | p = 0.001 |
| g. Genital HPV infection causes external anogenital warts (True) | 61.2% | 38.8% | 81.8% | 18.2% | 73.9% | 26.1% | 52.1% | 47.9% | p<0.001 |
| h. Genital HPV types usually associated with external anogenital warts differ from types usually associated with cervical dysplasia and cervical cancer (True) | 51.4% | 48.6% | 64.3% | 35.7% | 43.5% | 56.5% | 49.0% | 51.0% | p = 0.002 |
| i. External anogenital warts increase risk of cancer at the same site where the warts are located (False) | 51.9% | 48.1% | 56.6% | 43.4% | 41.3% | 58.7% | 52.5% | 47.5% | p = 0.064 |
| j. Treatment of external anogenital warts always permanently eliminates the causative infection (False) | 78.8% | 21.2% | 92.3% | 7.7% | 83.7% | 16.3% | 73.6% | 26.4% | p<0.001 |
| k. Available tests and procedures can determine the duration of a patient’s genital HPV infection (False) | 53.3% | 46.7% | 67.8% | 32.2% | 57.6% | 42.4% | 47.9% | 52.1% | p<0.001 |
| a. HPV vaccination gives lifelong protection against cervical cancer (False) | 55.2% | 44.8% | 51.0% | 49.0% | 38.0% | 62.0% | 59.0% | 41.0% | p<0.001 |
| b. HPV vaccines are live vaccines (False) | 69.1% | 30.9% | 72.7% | 27.3% | 57.6% | 42.4% | 69.5% | 30.5% | p = 0.028 |
| c. HPV vaccination is generally less effective in sexually active girls/women (True) | 65.4% | 34.6% | 72.0% | 28.0% | 63.0% | 37.0% | 62.7% | 37.3% | p = 0.114 |
| d. HPV vaccination will prevent >90% of cervical cancers (False) | 25.8% | 74.2% | 28.7% | 71.3% | 17.4% | 82.6% | 26.1% | 73.9% | p = 0.126 |
| e. HPV vaccines contain no viral DNA and are not infectious or oncogenic (True) | 64.6% | 35.4% | 76.2% | 23.8% | 60.9% | 39.1% | 60.6% | 39.4% | p = 0.003 |
| f. Available HPV vaccines protect against all of the HPV types that can cause cervical cancer (False) | 76.4% | 23.6% | 81.8% | 18.2% | 76.1% | 23.9% | 73.4% | 26.6% | p = 0.148 |
| g. HPV vaccination may protect against other types of cancer in addition to cervical cancer (True) | 32.6% | 67.4% | 53.8% | 46.2% | 50.0% | 50.0% | 21.8% | 78.2% | p<0.001 |
| h. Available HPV vaccines are not licensed for use in adolescent boys in Ireland (True) | 49.3% | 50.7% | 46.9% | 53.1% | 29.3% | 70.7% | 53.4% | 46.6% | p<0.001 |
| i. Vaccinated females will no longer need to have smears (False) | 95.3% | 4.7% | 95.8% | 4.2% | 91.3% | 8.7% | 94.3% | 5.7% | p = 0.134 |
| j. All available HPV vaccines protect against genital warts (False) | 71.3% | 28.7% | 80.4% | 19.6% | 57.6% | 42.4% | 69.9% | 30.1% | p = 0.001 |
1 test of association between practitioner group (female GP/male GP/practice nurse) and whether or not they answered the question correctly (correct/incorrect); whether the statement is true or false is indicted in brackets following each statement
2 includes subjects who provided the wrong answer, who indicated that they were unsure, and who declined to answer